Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STX209 for Irritability in Fragile X Syndrome
NCT00788073Phase 2Completed
- Sponsor
- Seaside Therapeutics
- Start
- Nov 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of arbaclofen in Fragile X syndrome (FXS), sponsored by Seaside Therapeutics. Started Nov 2008; status: completed.
02
Drugs
arbaclofen
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT00788073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00788073.